232 related articles for article (PubMed ID: 23504768)
1. Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer.
Woo J; Palmisiano N; Tester W; Leighton JC
Cancer; 2013 Jun; 119(11):1941-50. PubMed ID: 23504768
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
3. Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases.
Feng QY; Wei Y; Chen JW; Chang WJ; Ye LC; Zhu DX; Xu JM
World J Gastroenterol; 2014 Apr; 20(15):4263-75. PubMed ID: 24764664
[TBL] [Abstract][Full Text] [Related]
4. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.
Siu LL; Shapiro JD; Jonker DJ; Karapetis CS; Zalcberg JR; Simes J; Couture F; Moore MJ; Price TJ; Siddiqui J; Nott LM; Charpentier D; Liauw W; Sawyer MB; Jefford M; Magoski NM; Haydon A; Walters I; Ringash J; Tu D; O'Callaghan CJ
J Clin Oncol; 2013 Jul; 31(19):2477-84. PubMed ID: 23690424
[TBL] [Abstract][Full Text] [Related]
5. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.
Bouché O; Beretta GD; Alfonso PG; Geissler M
Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S1-10. PubMed ID: 20189053
[TBL] [Abstract][Full Text] [Related]
6. Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials.
Khattak MA; Martin H; Davidson A; Phillips M
Clin Colorectal Cancer; 2015 Jun; 14(2):81-90. PubMed ID: 25666296
[TBL] [Abstract][Full Text] [Related]
7. Spotlight on panitumumab in metastatic colorectal cancer.
Keating GM
BioDrugs; 2010 Aug; 24(4):275-8. PubMed ID: 20623992
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
9. Integration of panitumumab into the treatment of colorectal cancer.
Gravalos C; Cassinello J; García-Alfonso P; Jimeno A
Crit Rev Oncol Hematol; 2010 Apr; 74(1):16-26. PubMed ID: 19616446
[TBL] [Abstract][Full Text] [Related]
10. Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer.
Hendifar A; Tan CR; Annamalai A; Tuli R
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1051-61. PubMed ID: 24898788
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of cetuximab in therapy of metastatic colorectal cancer: a system evaluation].
Hou SH; Liang XB; Bai WQ; Yang J; Yan D; Zhang X; Wang LC
Zhonghua Yi Xue Za Zhi; 2009 May; 89(20):1387-90. PubMed ID: 19671328
[TBL] [Abstract][Full Text] [Related]
12. Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today?
Peeters M; Price T; Van Laethem JL
Oncologist; 2009 Jan; 14(1):29-39. PubMed ID: 19144681
[TBL] [Abstract][Full Text] [Related]
13. Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories.
Cheng L; Ren W; Xie L; Li M; Liu J; Hu J; Liu BR; Qian XP
Cancer Chemother Pharmacol; 2014 Jul; 74(1):1-13. PubMed ID: 24916545
[TBL] [Abstract][Full Text] [Related]
14. RAS Mutations Beyond KRAS Exon 2: A Review and Discussion of Clinical Trial Data.
Cannon TL; Kokon MA; Shafqat S; Deeken JF
Curr Treat Options Oncol; 2015 Jul; 16(7):33. PubMed ID: 26050230
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy in advanced colorectal cancer: more data, more questions.
Ochenduszko SL; Krzemieniecki K
Anticancer Drugs; 2010 Sep; 21(8):737-48. PubMed ID: 20631611
[TBL] [Abstract][Full Text] [Related]
16. Panitumumab: a review of its use in metastatic colorectal cancer.
Keating GM
Drugs; 2010 May; 70(8):1059-78. PubMed ID: 20481659
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer.
Okada Y; Miyamoto H; Goji T; Takayama T
Digestion; 2014; 89(1):18-23. PubMed ID: 24458108
[TBL] [Abstract][Full Text] [Related]
18. Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer.
Lee MS; Kopetz S
Clin Colorectal Cancer; 2015 Dec; 14(4):203-18. PubMed ID: 26077270
[TBL] [Abstract][Full Text] [Related]
19. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
Patel DK
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor inhibitors in first-line for metastatic colorectal cancer with ras wild-type: a perspective based on pharmacological costs.
Giuliani J; Bonetti A
Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):243-248. PubMed ID: 28649886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
